Loading
DocGo Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Burdiek Michael J, was filed 23 May 2025.
DocGo Inc.: what insiders have been doing
DocGo Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 21 October 2026, brought 10 filings signed by 8 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought DocGo Inc. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade.
With 10 filings in twelve months, the company is quieter than the median of 22 filings across the 5,454 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 12 purchases and 10 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 322.2 m USD and net income at -182.4 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
111
Thresholds
n/a
Buy Volume
€348,650
12 ops. · all time
Sell Volume
€1M
10 ops. · all time
Who traded when
BuySaleMichael J. Burdiek2 buys
Lee Bienstock1 buy
Norman Rosenberg1 buy
Stephen K. M.D. Klasko1 buy
Stephen Sugrue1 buy
Since the insiders bought
- -54.7%Entry US$1.39 · Close at T+365 US$0.63
- -59.2%Entry US$1.40 · Close at T+365 US$0.57
- -59.2%Entry US$1.40 · Close at T+365 US$0.57
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.26
Analyst consensus
4 analysts2.40/5
US$1.00Target US$1.88(+625%)US$3.00
Income statement
RevenueUS$322.2M
Gross profitUS$98.8M31% margin
EBITDA-US$73.5M-23% margin
Net income-US$182.4M-65.3% margin
Valuation
PER (forward)1.8x
P/Book0.2x
Beta0.97
Balance sheet & cash
Market capUS$25.6M
Total debtUS$29.2M
Free Cash FlowUS$27M
Debt / Equity27%
Profitability & ownership
ROE-107.8%
ROA-19.8%
% insiders3.1%
% institutions38.7%
Last declaration on 14 May 2026
Declarations111 total
15,644 shares@ US$0.590.014% mcap1.1% of flowCommon StockSEC:0001920525-26-000004:0
18,811 shares@ US$0.570.017% mcap1.4% of flowCommon StockSEC:0001920525-26-000002:0
321,055 shares0Common StockSEC:0001917263-25-000004:0
150,000 shares0Common StockSEC:0001892208-25-000003:0
150,000 shares0Common StockSEC:0001825203-25-000004:0
429,405 shares0Common StockSEC:0001439758-25-000004:0
100,000 shares0Common StockSEC:0001331867-25-000004:0
150,000 shares0Common StockSEC:0001324293-25-000004:0
150,000 shares0Common StockSEC:0001258177-25-000004:0
1,113,495 shares0Common StockSEC:0001920525-25-000004:0
100,000 shares0Common StockSEC:0001213900-25-086890:0
5,813 shares@ US$1.524.0% of flowCommon StockSEC:0001822359-25-000070:0
11,332 shares@ US$1.527.3% of flowCommon StockSEC:0001822359-25-000069:0
18,597 shares@ US$1.523.5% of flowCommon StockSEC:0001822359-25-000068:0
10,000 shares@ US$1.3312.4% of flowCommon StockSEC:0001822359-25-000056:0
Canonical exit: 21 Aug 2025 (T+90)
15,565 shares@ US$1.442.9% of flowCommon StockSEC:0001822359-25-000053:0
15,000 shares@ US$1.4320.1% of flowCommon StockSEC:0001822359-25-000054:0
Canonical exit: 13 Aug 2025 (T+90)
15,000 shares@ US$1.49100.0% of flowCommon StockSEC:0001822359-25-000050:0
Canonical exit: 12 Aug 2025 (T+90)
15,000 shares@ US$1.479.8% of flowCommon StockSEC:0001822359-25-000048:0
Canonical exit: 12 Aug 2025 (T+90)
15,000 shares@ US$1.543.0% of flowCommon StockSEC:0001822359-25-000047:0
Canonical exit: 12 Aug 2025 (T+90)
10,000 shares@ US$1.446.8% of flowCommon StockSEC:0001822359-25-000049:0
Canonical exit: 12 Aug 2025 (T+90)
5,614 shares@ US$2.687.3% of flowCommon StockSEC:0001822359-25-000032:0
18,742 shares@ US$2.646.6% of flowCommon StockSEC:0001822359-25-000030:0
8,004 shares@ US$2.689.8% of flowCommon StockSEC:0001822359-25-000031:0
77,520 shares0Common StockSEC:0001822359-25-000026:0
25 of 111 declarations
About DocGo Inc.
DocGo Inc. (ticker: DCGO) is a U.S.-listed healthcare services company traded on the NASDAQ in the United States. Founded in 2015 under the name Ambulnz, the company was built around a simple thesis: healthcare delivery can be more efficient when clinical care, transport logistics, and proprietary technology are combined into one operating platform. DocGo is headquartered in New York, placing it in a highly competitive U.S. healthcare market where scale, contracting discipline, and operational execution matter as much as clinical capability.
The company’s business is organized around two core pillars: Mobile Health Services and Transportation Services. Mobile Health includes in-home and on-site clinical evaluations, diagnostics, triage, treatment, medication administration, and other care delivery programs that bring services closer to the patient. Transportation Services cover emergency response capabilities as well as non-emergency medical transport, including ambulance and wheelchair transport. In practice, DocGo positions itself as a bridge between telehealth and physical care delivery, using technology to dispatch teams, manage patient workflows, and coordinate services across partners.
Read moreShow less
From a competitive standpoint, DocGo operates at the intersection of mobile care, virtual care, and medical transportation. That positioning is relevant because U.S. healthcare systems continue to face pressure from hospital overcrowding, staffing shortages, cost containment efforts, and the need to shift care into lower-cost settings. DocGo’s value proposition is that it can stand up contracted services quickly and operate them at scale for health systems, payers, and public-sector customers. The company’s footprint is primarily in the United States, though it also has a presence in the United Kingdom, giving it a modest international dimension.
Recent developments have centered on expanding the company’s care delivery platform and broadening its service mix. In October 2025, DocGo acquired SteadyMD, a virtual care platform, to expand telehealth capabilities across all 50 states. The company also announced new programs and partnerships in late 2025 and early 2026, including longitudinal care services, care-gap closure initiatives, and additional mobile health offerings. Management commentary has emphasized growth in core operating volumes and a continued transition away from pandemic-related work toward more durable, recurring healthcare contracts. For equity investors, DocGo remains a growth-oriented healthcare platform with an asset-light, technology-enabled model, but one that still depends on contract wins, reimbursement dynamics, and disciplined margin execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
